Hema Diagnostic Systems Announces the Initial Sale of Our Rapid 1-2-3(R) Hema Cassette Malaria PF/PV Through "WHO Procurement"
MIRAMAR, FL / ACCESSWIRE / January 24, 2017 / Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTC PINK: GNBT), announced today the receipt of the first initial order from the World Health Organization (WHO) Procurement, Malaysia for our Rapid 1-2-3® Hema Cassette Malaria PF/PV.
In February 2016, Hema Diagnostic Systems (HDS) and the World Health Organization (WHO) entered into a Long Term Agreement for the sale and purchase of our HDS Rapid 1-2-3 Hema Cassette Malaria PF/PV and Rapid 1-2-3 Hema Cassette Malaria PF on a worldwide basis. These diagnostics were previously evaluated and approved by the WHO following individual 18 month evaluations to determine the Sensitivity and Specificity of each diagnostic.
In December 2016, HDS received its first initial order from WHO Procurement for the Rapid 1-2-3 Hema Cassette Malaria PF/PV WHO approved device. This order was an Emergency Requirement destined for use in Damascus, Syria. HDS has worked closely with WHO Procurement to deliver this order, which represents the first of three WHO approved devices. Additional WHO approved HDS devices include the Rapid 1-2-3 Hema Cassette Malaria PF and, in December 2016, the Rapid 1-2-3 Hema Cassette Malaria PF/Pan.
Lawrence Salvo, President and CEO of Hema Diagnostic Systems, stated the following upon receipt of the WHO Procurement order: "HDS welcomes the opportunity to provide our Rapid 1-2-3 Hema Cassette Malaria PF/PV to the World Health Organization destined for Damascus, Syria, and we look forward to participating in further requirements for our Rapid 1-2-3 Hema Cassette Malaria PF, as well as for our most recent WHO approved Rapid 1-2-3 Hema Cassette Malaria PF/Pan."
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales, and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results.
For more information, please contact:
Email: info@rapid123.com
SOURCE: Hema Diagnostic Systems, LLC
